Viking Therapeutics, Up 62% Since August, Undercuts A Buy Zone Despite Key Win

Group 1 - Viking Therapeutics (VKTX) stock experienced a decline after the company reported over-enrollment in its final-phase study for the weight-loss drug VK2735, with 4,650 patients enrolled instead of the targeted 4,500 [1] - The study focuses on patients who are overweight or have obesity with at least one related condition, indicating a significant interest in the drug's potential market [1] - Leerink Partners analyst Thomas Smith highlighted the importance of this over-enrollment in a report to clients, suggesting it may have implications for the study's outcomes and future stock performance [1] Group 2 - Viking Therapeutics has seen its Relative Strength Rating rise to 89, indicating improved performance relative to other stocks [2]